Core Viewpoint - On November 17, 2023, Boyuan Co., Ltd. experienced a decline of 3.80% in stock price, with a trading volume of 299 million yuan, indicating potential market concerns regarding the company's performance and investor sentiment [1]. Financing Summary - On the same day, Boyuan Co., Ltd. had a financing buy-in amount of 25.66 million yuan and a financing repayment of 35.66 million yuan, resulting in a net financing outflow of 9.99 million yuan [1]. - As of November 17, the total financing and securities lending balance for Boyuan Co., Ltd. was 169 million yuan, which represents 5.56% of its circulating market value [1]. - There were no shares sold or repaid in the securities lending segment on November 17, with a remaining balance of 0 yuan [1]. Company Overview - Boyuan Co., Ltd., established on August 6, 2008, is located in Shouguang City, Shandong Province, and specializes in the research, production, and sales of fine chemicals, including organic and inorganic iodides, precious metal catalysts, luminescent materials, and hexamethyldisilazane [2]. - The company's revenue composition includes iodides (74.56%), specialty functional chemicals (12.79%), trading business (9.94%), and others (2.72%) [2]. - For the period from January to September 2025, Boyuan Co., Ltd. reported a revenue of 1.073 billion yuan, reflecting a year-on-year growth of 6.60%, while the net profit attributable to shareholders decreased by 22.53% to 132 million yuan [2]. Shareholder Information - As of November 10, 2025, Boyuan Co., Ltd. had 11,900 shareholders, a decrease of 12.88% from the previous period, with an average of 2,813 circulating shares per shareholder, an increase of 14.78% [2]. - The company has distributed a total of 88.41 million yuan in dividends since its A-share listing [3]. - Notable new institutional shareholders include Zhonghang New Start Flexible Allocation Mixed A, holding 1.3456 million shares, and several other funds that have recently entered the shareholder list [3].

Core Viewpoint - The stock price of Boyuan Co., Ltd. has increased by 5.22% on November 14, reaching 93.30 CNY per share, with a total market capitalization of 12.469 billion CNY, indicating a continuous upward trend over the past three days with a cumulative increase of 5.45% [1] Company Overview - Boyuan Co., Ltd. is located in Shouguang City, Shandong Province, and was established on August 6, 2008. The company specializes in the research, production, and sales of fine chemicals, including organic iodides, inorganic iodides, precious metal catalysts, luminescent materials, and hexamethyldisilazane. It also engages in the recycling of iodine and precious metal materials [1] - The main revenue composition of Boyuan Co., Ltd. includes iodides (74.56%), specialty functional chemicals (12.79%), trading business (9.94%), and others (2.72%) [1] Shareholder Information - Among the top ten circulating shareholders of Boyuan Co., Ltd., a fund under AVIC Fund ranks as a significant holder. The AVIC New Start Flexible Allocation Mixed A Fund (005537) entered the top ten shareholders in the third quarter, holding 1.3456 million shares, which accounts for 4.03% of the circulating shares. The estimated floating profit today is approximately 6.2304 million CNY [2] - During the three-day increase, the floating profit earned was 616.31 thousand CNY [2] Fund Manager Profile - The fund manager of AVIC New Start Flexible Allocation Mixed A Fund (005537) is Han Hao, who has been in the position for 7 years and 338 days. The total asset size of the fund is 15.589 billion CNY, with the best fund return during his tenure being 205.01% and the worst being -18.95% [3]

Core Insights - On November 12, Boyuan Co., Ltd. saw a stock increase of 1.35% with a trading volume of 211 million yuan [1] - The company reported a net financing purchase of 7.72 million yuan on the same day, with a total financing balance of 175 million yuan, accounting for 6.06% of its market capitalization [1][2] Company Overview - Boyuan Co., Ltd. is located in Shouguang City, Shandong Province, and was established on August 6, 2008, with a planned listing date of December 11, 2024 [2] - The company specializes in the research, production, and sales of fine chemicals, including organic iodides, inorganic iodides, precious metal catalysts, luminescent materials, and hexamethyldisilazane [2] - The revenue composition includes iodides (74.56%), specialty functional chemicals (12.79%), trading business (9.94%), and others (2.72%) [2] Financial Performance - For the period from January to September 2025, Boyuan Co., Ltd. achieved a revenue of 1.073 billion yuan, representing a year-on-year growth of 6.60% [2] - The net profit attributable to shareholders was 132 million yuan, showing a year-on-year decrease of 22.53% [2] Shareholder Information - As of November 10, 2025, the number of shareholders for Boyuan Co., Ltd. was 11,900, a decrease of 12.88% from the previous period [2] - The average circulating shares per person increased by 14.78% to 2,813 shares [2] - The company has distributed a total of 88.408 million yuan in dividends since its A-share listing [3] Institutional Holdings - As of September 30, 2025, several new institutional shareholders have entered, including: - China Aviation New Start Flexible Allocation Mixed A (005537) as the second-largest shareholder with 1.3456 million shares [3] - Hong Kong Central Clearing Limited as the third-largest shareholder with 964,400 shares [3] - Other new shareholders include Yongying New Materials and Penghua Huizhi [3]

Market Outlook - The market for inorganic iodides is expected to grow significantly due to increasing medical expenditures driven by rising living standards, aging populations, and heightened health awareness [2][3] - The demand for contrast agents in the diagnosis of diseases such as tumors, cardiovascular diseases, and neurological disorders is projected to steadily increase, expanding the domestic contrast agent market [2][3] - The rapid development of the global pharmaceutical industry, particularly in new drug research and development, is expected to further drive the demand for high-quality pharmaceutical intermediates [3] Production Capacity Expansion - The company is establishing a new production project for 4,000 tons/year of inorganic iodides to enhance capacity and diversify its product offerings, focusing on high-value products for pharmaceutical and electronic applications [4] Competitive Advantages - **Resource Recycling and Service Integration**: The company has developed a unique "iodine resource recycling" industry chain, reducing reliance on imported iodine and lowering procurement costs while providing integrated solutions to clients [4] - **Regulatory Compliance and Scale**: As a leading iodine resource utilization enterprise, the company has a robust capacity for iodine recycling and complies with environmental regulations, enhancing collaboration with clients [4][5] - **Technological Innovation**: The company emphasizes continuous technological advancement and has established a comprehensive R&D and talent incentive system, leading to industry-leading processes and patented technologies [5] - **Quality Control and Client Relationships**: A thorough quality control system ensures product quality, with core products certified by authoritative bodies, fostering long-term trust with major clients [5] Shareholder Information - The company plans to release 19,630,000 shares from lock-up on December 11, 2025, with no current plans for shareholder reductions communicated [5]

Group 1: Iodine and Its Applications - Iodine and its derivatives are crucial raw materials in medical, agricultural, industrial, and nutritional fields, widely used in various product formulations as key components or catalysts [2] - The downstream application structure of iodine includes three core areas: X-ray contrast agents, pharmaceutical manufacturing, and LCD panel manufacturing, which together account for approximately 63% of global consumption [2] - Major iodine production is concentrated in Chile, Japan, and the United States, with these three countries accounting for 88% of global sales [2][3] Group 2: Company Product Overview - The company’s inorganic iodide products include potassium iodide, potassium iodate, sodium iodide, hydriodic acid, and cuprous iodide, primarily used in pharmaceuticals, pesticides, feed, and optoelectronic materials [3] - Organic iodide products include trimethylsilyl iodide and methyl iodide, with trimethylsilyl iodide being used as a protecting group in organic synthesis, particularly in the production of antibiotics [3] Group 3: Strategic Developments - The company signed a strategic cooperation framework agreement with a technology partner in October 2025 to enhance the industrialization of sulfide solid electrolyte technology through resource integration and innovation [3] - The company’s 4000 tons/year inorganic iodide production project is expected to be completed by the end of 2025, with a production capacity of 300 tons of lithium iodide upon full operation [3]

Core Viewpoint - The stock of Shandong Boyuan Pharmaceutical Chemical Co., Ltd. has experienced significant fluctuations, with a year-to-date increase of 151.82% but a recent decline of 3.42% over the last five trading days [1] Group 1: Company Overview - Shandong Boyuan Pharmaceutical Chemical Co., Ltd. was established on August 6, 2008, and is located in Shouguang City, Shandong Province [2] - The company specializes in the research, production, and sales of fine chemicals, including organic iodides, inorganic iodides, precious metal catalysts, luminescent materials, and hexamethyldisilazane [2] - The main revenue composition includes iodides (74.56%), specialty functional chemicals (12.79%), trading business (9.94%), and others (2.72%) [2] Group 2: Financial Performance - For the period from January to September 2025, Boyuan achieved operating revenue of 1.073 billion yuan, representing a year-on-year growth of 6.60% [2] - The net profit attributable to the parent company was 132 million yuan, showing a year-on-year decrease of 22.53% [2] - Cumulative cash dividends since the A-share listing amount to 88.408 million yuan [3] Group 3: Shareholder and Market Activity - As of October 20, 2025, the number of shareholders increased by 25.58% to 13,300, with an average of 2,502 circulating shares per person, a decrease of 20.37% [2] - The stock has appeared on the "Dragon and Tiger List" six times this year, with the most recent appearance on October 17, where it recorded a net buy of -20.2738 million yuan [1] - Major shareholders include various new institutional investors, with significant holdings from funds such as Zhonghang New Start Flexible Allocation Mixed A and Hong Kong Central Clearing Limited [3]

Core Insights - On October 24, Boyuan Co., Ltd. saw a stock price increase of 14.34% with a trading volume of 902 million yuan [1] - The company experienced a net financing outflow of 982.88 million yuan on the same day, with a total financing and securities balance of 1.92 billion yuan [1][2] Financing and Trading Data - On October 24, Boyuan Co., Ltd. had a financing purchase of 8970.56 million yuan, with a current financing balance of 1.92 billion yuan, representing 5.58% of the circulating market value [2] - There were no short sales or repayments on the same day, with a short balance of 0.00 yuan [2] Company Overview - Boyuan Co., Ltd. is located in Shouguang City, Shandong Province, and was established on August 6, 2008, with a listing date of December 11, 2024 [2] - The company specializes in the research, production, and sales of fine chemicals, including organic iodides, inorganic iodides, precious metal catalysts, luminescent materials, and hexamethyldisilazane [2] - The main revenue composition includes iodides (74.56%), specialty functional chemicals (12.79%), trading business (9.94%), and others (2.72%) [2] Shareholder and Financial Performance - As of October 20, the number of shareholders for Boyuan Co., Ltd. was 13,300, an increase of 25.58% from the previous period, with an average of 2502 circulating shares per person, a decrease of 20.37% [3] - For the period from January to September 2025, the company reported a revenue of 1.073 billion yuan, a year-on-year increase of 6.60%, while the net profit attributable to shareholders decreased by 22.53% to 132 million yuan [3] Dividend and Institutional Holdings - Boyuan Co., Ltd. has distributed a total of 88.408 million yuan in dividends since its A-share listing [4] - As of September 30, 2025, several new institutional shareholders have emerged among the top ten circulating shareholders, including Zhonghang New Start Flexible Allocation Mixed A and Hong Kong Central Clearing Limited [4]

Core Viewpoint - The company announced a strategic cooperation framework agreement with a technology firm, focusing on diversified collaboration around sulfide solid electrolyte systems [1] Group 1: Strategic Developments - The company has completed the independent research and process development of high-purity lithium iodide [1] - A production project for inorganic iodides with a capacity of 4,000 tons per year is expected to be completed by the end of 2025 and will enter trial production [1] Group 2: Production Capacity and Market Considerations - Once fully operational, the project will achieve an annual production capacity of 300 tons of lithium iodide [1] - The subsequent commercialization process requires customer validation, and there is uncertainty regarding the formation of a scaled market for sales [1]

Core Viewpoint - The company has signed a strategic cooperation framework agreement with a technology firm, focusing on diversified collaboration around sulfide solid electrolyte systems [1] Group 1: Strategic Developments - The company announced the completion of independent research and process stabilization for high-purity lithium iodide [1] - A production project for inorganic iodides with a capacity of 4,000 tons per year is expected to be completed by the end of 2025, with trial production commencing thereafter [1] Group 2: Production Capacity and Market Considerations - Once fully operational, the project will have an annual production capacity of 300 tons of lithium iodide [1] - The subsequent commercialization process requires customer validation, indicating uncertainty in achieving large-scale market sales [1]

Group 1 - The stock of Baoyuan Co., Ltd. increased by 15.91% on October 16, with a trading volume of 1.016 billion yuan [1] - On the same day, Baoyuan Co. had a financing buy-in amount of 80.791 million yuan and a net financing buy-in of 17.657 million yuan, with a total financing and securities balance of 119 million yuan [1] - The current financing balance of Baoyuan Co. is 119 million yuan, accounting for 4.25% of its circulating market value [1] Group 2 - Baoyuan Co., Ltd. is located in Shouguang City, Shandong Province, and was established on August 6, 2008, with its main business involving the research, production, and sales of fine chemicals [2] - The company's main business revenue composition includes 74.56% from iodides, 12.79% from specialty functional chemicals, 9.94% from trading, and 2.72% from other sources [2] - For the first half of 2025, Baoyuan Co. achieved an operating income of 747 million yuan, a year-on-year increase of 7.39%, while the net profit attributable to the parent company was 99.0429 million yuan, a year-on-year decrease of 19.09% [2] Group 3 - Baoyuan Co. has cumulatively distributed 88.408 million yuan in dividends since its A-share listing [3]